Overview
APVO market data
Price History
APVO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for APVO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".Benzinga · Jul 8, 2026, 8:05 PM
8-K filing — Aptevo Therapeutics Inc. (APVO)SEC EDGAR · Jun 30, 2026, 8:05 PM
Andy Hill Cancer Research Endowment Awards Aptevo Therapeutics $1.5M Non-Dilutive Research Grant For APVO451.Benzinga · Jun 30, 2026, 12:20 PM
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".Benzinga · May 27, 2026, 8:20 PM
Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology ProgramsBenzinga · May 27, 2026, 12:09 PM